PortViewPortView
Galapagos N.V. logo

Galapagos N.V. (GLPG) Stock Analysis

NASDAQHealthcareBiotechnology

$27.98+1.71%
1-year price historyRange $26.08 – $37.62
52-week range$27.98
$24.74$37.78

What Galapagos N.V. does

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Key metrics

Market cap
$1.84B
P/E (TTM)
3.21
EPS (TTM)
$8.71
Beta
0.30
Dividend yield
0.00%
Revenue / share
$13.44
50-day avg
$30.32
200-day avg
$32.15
52-week high
$37.78
52-week low
$24.74
CEO
Henry O. Gosebruch

ETFs linked to GLPG

Broad-market and Healthcare sector ETFs an investor holding Galapagos N.V. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GLPG fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze GLPG in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Galapagos N.V.?
Galapagos N.V. trades under the ticker GLPG on NASDAQ.
Which exchange is GLPG listed on?
GLPG is listed on NASDAQ.
What sector does Galapagos N.V. operate in?
Galapagos N.V. is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze GLPG in a portfolio?
PortView shows GLPG's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.